Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Axios on your phone

Get breaking news and scoops on the go with the Axios app.

Download for free.

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

A researcher in San Francisco uses the Illumina NextSeq 550 genetic sequencer to decode a COVID-19 infection. Photo: Jessica Christian/The San Francisco Chronicle via Getty Images

The head of the world's leading genetic sequencing company predicts a future where genomic data will increasingly drive health care.

Why it matters: As our ability to read genes gets faster and cheaper, genetic sequencing could pave the way for everything from enhanced disease surveillance to truly personalized care.

Driving the news: Illumina, which controls roughly 90% of the market for genetic sequencing machines in the U.S., announced earlier this week it earned record revenue of $1.09 billion in the first quarter of 2021.

  • The company is projecting revenue growth of 25–28% in fiscal year 2021 over the previous year.

Details: That growth is due in large part to "the extraordinarily massive and urgent human needs of the pandemic," Illumina CEO Francis DeSouza told Axios in an interview.

  • Genetic sequencing machines like the ones produced by Illumina were how scientists were able to rapidly decode the genome of SARS-CoV-2 and start building both tests and the mRNA vaccines that will ultimately curb the pandemic.
  • Our ability to track more dangerous virus mutations like B.1.1.7 was only possible because gene sequencing technology had gotten faster, cheaper and more widespread.

What's next: It cost $1,000 for Illumina to sequence a human genome in 2014, but the company expects to reach the $100 level within a couple of years.

  • Ultra-cheap sequencing — combined with an ever-increasing understanding of the genome — will result in genetics becoming "the foundational element of your health record," he says.

What to watch: The growth of liquid biopsies — tests that can find the genetic markers of cancer in blood samples.

  • Illumina is in the process of a $7.1 billion acquisition of Grail, a company that has developed liquid biopsies for dozens of cancers, but the Federal Trade Commission last week moved to block the acquisition on competitive grounds.
  • DeSouza contests the FTC's case that the acquisition will ultimately increase the cost of liquid biopsies, arguing Illumina can help get Grail's diagnostics to market faster and accelerate reimbursements for "underserved populations that can't afford the test."

The bottom line: Just as WWI helped accelerate the development of airplanes and WWII nuclear technology, "I believe we will look back and view the pandemic as ushering the era of biology and the era of the genome," says DeSouza.

Go deeper

Apr 8, 2021 - Science

How AI could revolutionize biology — and vice versa

Illustration: Sarah Grillo/Axios

Cutting-edge, machine-learning techniques are increasingly being adapted and applied to biological data, including for COVID-19.

The big picture: Discovering and developing a new drug typically takes more than a decade and costs on average close to $1 billion, making it difficult to build a cache of pharmaceuticals to fight future pandemics or stop intractable diseases.

51 mins ago - World

One-year anniversary of Beirut blast marked by grief, anger

White roses are seen on portraits of victims of last year's Beirut port blast in the Lebanese capital, as Lebanon marks on August 4, 2021. Photo: Joseph Eid/AFP via Getty Images

Fluctuating between feelings of sadness, grief and anger, Beirut residents on Wednesday marked the one-year anniversary of the port explosion that killed more than 200 people and injured thousands of others.

The big picture: No senior official has been held accountable for the blast, which was caused by a large amount of ammonium nitrate stored unsafely at the port for years, per Reuters.

Kendall Baker, author of Sports
1 hour ago - Sports

The NCAA's summer of change

Illustration: Aïda Amer/Axios

The college sports landscape has changed more this summer than at any other point in history, as the NCAA grapples with new rules and shifting power dynamics.

The state of play: When NCAA competition resumes this fall, everyone involved — from student-athletes and coaches, to universities and fans — will be entering a new world.